Another pharmaceutical therapeutic option is the enzymatic induction of CYP3A4 by rifampicin, which has been successfully used in patients with CYP24A1 mutations to diminish hypercalcemia and hypercalciuria [23]. This evidence concerns the gene CYP3A4 and hypercalcemia disease.